<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064436</url>
  </required_header>
  <id_info>
    <org_study_id>IM038-010</org_study_id>
    <secondary_id>2021-001986-19</secondary_id>
    <nct_id>NCT05064436</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis</brief_title>
  <official_title>A Phase 1, Open-label, Multi-part Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution, and CNS Signal of the Positron Emission Tomography Ligand 11C-BMS-986196 in Healthy Participants After Intravenous Administration and to Evaluate the Safety, Tolerability, Kinetics, and CNS Signal Repeatability of 11C-BMS-986196 After Repeat Intravenous Administration in Participants With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, kinetics, biodistribution&#xD;
      and central nervous system signal of 11C-BMS-986196 after intravenous (IV) administration in&#xD;
      healthy participants and after repeat IV administration in participants with multiple&#xD;
      sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of TEAEs by Maximum Severity</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious TEAEs</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of TEAEs by System Organ Class</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of TEAEs by Preferred Term</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation dosimetry calculated from PET-CT images in healthy participants</measure>
    <time_frame>At day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Image acquisition window after administration of 11C-BMS-986196</measure>
    <time_frame>After 2nd 11C-BMS-986196 administration, Up to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Test-retest repeatability based on standardized uptake value (SUV) of CNS PET-MRI images in participants with MS</measure>
    <time_frame>After 2nd 11C-BMS-986196 administration, Up to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Test-retest repeatability based on volume of distribution (VT) of CNS PET-MRI images in participants with MS</measure>
    <time_frame>After 2nd 11C-BMS-986196 administration, Up to 6 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculated SUV in the brain</measure>
    <time_frame>After 2nd 11C-BMS-986196 administration, Up to 6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated VT in the brain</measure>
    <time_frame>After 2nd 11C-BMS-986196 administration, Up to 6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>Part A - Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - Participants with MS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>11C-BMS-986196</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part A - Healthy Participants</arm_group_label>
    <arm_group_label>Part B - Participants with MS</arm_group_label>
    <other_name>BMS-986196</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit: www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        For Parts A &amp; B:&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to 34 kg/m2, inclusive, and total body weight ≥ 50 kg&#xD;
&#xD;
          -  Documentation of normal Allen's test result at Screening and on PET scanning days in&#xD;
             the arm that will be used for arterial line placement&#xD;
&#xD;
        For Part A only:&#xD;
&#xD;
        • Healthy male and female participants without clinically significant deviation from normal&#xD;
        in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical&#xD;
        laboratory determinations&#xD;
&#xD;
        For Part B only:&#xD;
&#xD;
          -  Male or female participant diagnosed with MS according to the 2017 revisions of the&#xD;
             McDonald diagnostic criteria&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score between 0 to 6.5, inclusive, at&#xD;
             Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For Parts A &amp; B:&#xD;
&#xD;
          -  Benign MS defined as a baseline EDSS of 2.0 with MS diagnosis ≥ 10 years prior to Day&#xD;
             1. Spinal MS without clinical or radiological evidence of brain lesions. Any other&#xD;
             combination of clinical and radiological data suggestive of an absence of inflammatory&#xD;
             brain lesions.&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study treatment administration and/or any minor&#xD;
             surgery within 2 weeks of tracer administration&#xD;
&#xD;
        For Part A only:&#xD;
&#xD;
        • Any significant acute or chronic medical illness&#xD;
&#xD;
        For Part B only:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness (other than MS) posing a risk to the&#xD;
             participant's safety or negatively affecting the ability to detect CNS PET signal&#xD;
&#xD;
          -  MS relapse within 14 days prior to Day 1. Participants with a MS relapse within 30&#xD;
             days prior to Day 1 must agree to have their second PET scan scheduled on Day 1 or Day&#xD;
             2&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis (MS)</keyword>
  <keyword>Healthy Participants</keyword>
  <keyword>11C-BMS-986196</keyword>
  <keyword>PET tracer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

